Clesrovimab, a long-acting antibody for RSV prevention in infants, was reported to provide durable protection after a single 105 mg dose during the infants’ first RSV season. The statement aligns with early real-world value propositions for long-acting, lower-burden prophylaxis. The summary emphasizes protection against RSV lower respiratory tract disease across the season window, reflecting a key clinical endpoint for infant RSV immunization strategies. The single-dose format is a differentiator for feasibility compared with multi-dose regimens. As typical for immunization claims, confirmatory monitoring across broader populations and seasons will shape how clinicians incorporate the product into pediatric preventive care pathways.